Structure and stability of two polymorphs of creatine and its monohydrate by Arlin, Jean-Baptiste et al.
Structure and stability of two polymorphs 
of creatine and its monohydrate 
Article 
Accepted Version 
Arlin, J.­B., Bhardwaj, R. M., Johnston, A., Miller, G. J., 
Bardin, J., MacDougall, F., Fernandes, P., Shankland, K., 
David, W. I. F. and Florence, A. J. (2014) Structure and 
stability of two polymorphs of creatine and its monohydrate. 
Crystengcomm, 16 (35). pp. 8197­8204. ISSN 1466­8033 doi: 
https://doi.org/10.1039/c4ce00508b Available at 
http://centaur.reading.ac.uk/39201/ 
It is advisable to refer to the publisher’s version if you intend to cite from the 
work. 
To link to this article DOI: http://dx.doi.org/10.1039/c4ce00508b 
Publisher: Royal Society of Chemistry 
All outputs in CentAUR are protected by Intellectual Property Rights law, 
including copyright law. Copyright and IPR is retained by the creators or other 
copyright holders. Terms and conditions for use of this material are defined in 
the End User Agreement . 
www.reading.ac.uk/centaur 
CentAUR 
Central Archive at the University of Reading 
Reading’s research outputs online
  
PAPER  
 
 
 
View Journal | View Issue  
 
 
Structure and stability of two polymorphs of  
creatine and its monohydrate†  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
 
Jean-Baptiste Arlin,a Rajni M. Bhardwaj,b Andrea Johnston,b Gary J. Miller,b 
Julie Bardin,b Fiona MacDougall,c Philippe Fernandes,d Kenneth Shankland,e  
William I. F. Davidf and Alastair J. Florence*b  
 
An experimental search for crystalline forms of creatine including a variable temperature X-ray powder  
diffraction study has produced three polymorphs and a formic acid solvate. The crystal structures of creatine 
forms I and II were determined from X-ray powder diffraction data plus the creatine formic acid (1 : 1) solvate 
structure was obtained by single crystal X-ray diffraction methods. Evidence of a third poly- morphic form of 
creatine obtained by rapid desolvation of creatine monohydrate is also presented. The results highlight the role of 
automated parallel crystallisation, slurry experiments and VT-XRPD as power- ful techniques for effective physical 
form screening. They also highlight the importance of various com- plementary analytical techniques in structural 
characterisation and in achieving better understanding of the relationship between various solid-state forms. The 
structural relationships between various solid- state forms of creatine using the XPac method provided a rationale 
for the different relative stabilities of forms I and II of creatine with respect to the monohydrate form.  
 
 
cyclisation to form creatinine.8 The crystal structure of an 
anhydrous crystalline form has been reported very recently9  
Creatine (CTN; Scheme 1) is commercially available as a nutri- 
tional supplement, mainly in the form of CTN monohydrate. CTN 
is involved in the metabolic pathway for ATP formation in the 
muscle under anaerobic conditions.1 CTN supplements can 
increase muscle performance during strenuous exercise by 
maintaining the high turnover rates of ATP.2,3 Worldwide CTN 
sales were estimated at over 400 million dollars in 2009.  
The structure of CTN monohydrate has been studied 
previously using X-ray and neutron single crystal diffraction4-6 and 
has been reported to desolvate upon heating to produce an 
anhydrous crystalline form, although no structure was  
reported.7,8 Upon continued heating to between 503-533 K  
CTN undergoes a condensation reaction via an intramolecular  
using a combined approach of crystal structure prediction (CSP) 
and X-ray powder diffraction (XRPD) which matches with form II 
reported in this study.  
Different physical forms of molecular solids can display 
marked differences in their key physicochemical properties 
including melting point, solubility, dissolution and stability. Oral 
bioavailability and stability in the final dosage form are 
particularly two important properties for a marketed com- pound 
available for human consumption. Therefore, in order to explore 
the extent of physical form diversity and relationship amongst 
various physical forms of this important nutraceutical compound, 
an experimental screen was implemented using crystallisation 
from solution, slurrying, in situ desolvation and thermal 
approaches.10 Here we report the crystal structures of  
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Scheme 1 CTN molecule shown in zwitterionic form as found in the crystal 
structure of CTN monohydrate.  
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two polymorphs forms I and II and a 1 : 1 formic acid solvate of 
CTN. These crystal structures are further analysed in terms of 
crystal packing features and are compared to the known crystal 
structure of CTN monohydrate using the XPac method11 to identify 
the key intermolecular packing motifs that under- pin the physical 
form diversity of various forms of this com- pound. Also the 
relationships between crystal structures of the polymorphs and 
monohydrate and their interconversion12 is investigated. Evidence 
for a third polymorph (form III) of CTN prepared by rapid in situ 
desolvation is also presented. Due to limited availability of form III 
samples, only XRPD data and thermal analyses are presented.  
Experimental section  
 
 
Materials  
 
Samples of anhydrous CTN and CTN monohydrate were pur- 
chased from Sigma and used without further purification. The 
sample of anhydrous CTN as received was identified as a mixture 
of CTN monohydrate and CTN II by XRPD.  
Methods  
Automated parallel crystallisation  
67 solvents covering a wide range of physicochemical properties  
were used for solution crystallisations of creatine (see ESI,†  
Table S1) using an automated parallel crystallisation platform  
i.e. Chemspeed Accelerator SLT100.13 These crystallisations were 
carried out in duplicate. Solutions were prepared by adding excess 
solid in each solvent to ensure that solutions were satu- rated at the 
appropriate temperature prior to being filtered automatically into a 
clean crystallisation vessel. Crystallisation was induced by 
controlled cooling in filtered solutions.  
Due to poor solubility of CTN in majority of the tested 
solvents, slurry experiments were conducted for 51 solvents  
(see ESI,† Table S2). Following recrystallisation, suspended  
samples were reclaimed by filtration and were analysed to con-  
firm its identity using multisample foil transmission XRPD.  
 
 
Manual slurry experiment  
Approximately 100 mg of anhydrous CTN was placed in a vial  
and 5 ml of solvent was added. The mixture was left under stirring 
and suspended samples were analysed regularly using XRPD.  
 
 
Relative stabilities  
The relative stabilities of CTN I and II was assessed using com-  
petitive slurry experiments.14,15 A mixture of 51.2% of CTN I and 
48.8% CTN II was left to slurry in two different solvents (butyl 
acetate and isoamyl alcohol). The evolution of the mix- ture 
composition was analysed by ratioing the heights of a selected 
XRPD peak characteristic of each form. When the  
ratio became 0 or , the remaining phase was assessed as the  
most stable. Physical stabilities of CTN I and II were assessed  
 
 
 
 
 
by analysing the composition of the samples left under ambi- ent 
conditions (open bench) over a period of 3 months.  
 
 
Dynamic vapour sorption analysis  
Dynamic vapour sorption (DVS) experiments were conducted  
on DVS instrument from Surface Measurement Systems. Sam- ples 
were first exposed to 0% relative humidity (RH) followed by two 
hydration/dehydration cycles with humidity values varying from 
0%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 95%. 
The change of RH was controlled by the variation in the sample 
mass and it was changed when dm/dt was smaller than 0.001 mg 
min1.  
 
 
X-ray powder diffraction  
For crystalline form identification, a small quantity (10-50 mg)  
of sample was analysed using transmission foil XRPD data col-  
lected on a Bruker AXS D8 Advance transmission diffractome-  
ter equipped with / geometry, primary monochromated  
radiation (Cu K
1
  = 1.54056 Å), a Braun 1D position sensitive  
detector (PSD) or a Vantec PSD and an automated multi-  
position x-y sample stage. Samples were mounted on a 28 posi-  
tion sample plate supported on a polyimide (Kapton, 7.5 m  
thickness) film. Data were collected from each sample in the  
range 4-35° 2 with a 0.015° 2 step size and 1 s step1 count  
time (data collection time per sample ca. 40 minutes).16 Sam-  
ples were oscillated ±0.5 mm in the x-y plane at a speed of  
0.3 mm s1 throughout data collection to maximise particle  
sampling and minimise preferred orientation effects.  
For structure determination from X-ray powder diffraction data 
(SDPD) purposes, samples were loaded in a rotating 0.7 mm 
borosilicate glass capillary and mounted on a Bruker AXS D8 X-
ray powder diffractometer equipped with primary mono-  
chromator (Cu K
1
,  = 1.54056 Å) and Lynxeye PSD. Data  
were collected at room temperature in the range 2-70° 2 with a 
0.015° 2 step size, using a variable count time scheme17,18  
to improve the accuracy of the intensities at high angle. The  
diffraction pattern was indexed using the first twenty peaks with 
DICVOL0419 as implemented in the DASH structure solution 
package. Space group determination was carried out using a 
statistical assessment of systematic absences. A Pawley type 
refinement20 was used to extract the intensities and their 
correlations. Simulated annealing (SA), as implemented in DASH 
version 3.121 was used to solve the crystal structure from the 
powder pattern in direct space. The starting molecular geometry 
was obtained from the neutron single-crystal structure determination 
of CTN monohydrate [CSD refcode = CREATH05] in which CTN 
exists as a zwitterion. The zwitterionic state of form I, II and III of 
CTN was confirmed by ATR FTIR data (see  
ESI,† Fig. S1, Table S3). Plane-wave density functional theory  
calculations using the CASTEP22 program were conducted on  
CTN I, II and CTN monohydrate [CSD refcode = CREATH05]  
to check the accuracy of the zwitterion configuration (see ESI,†  
Fig. S2).23,24 For both structures, the best DASH solutions  
returned a 2 ratio (2 SA/2 Pawley) < 5 indicative of an excel-  
lent fit to the data. A restrained Rietveld refinement25 of the  
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global minimum solution obtained from SA was carried out in 
TOPAS Academic version 4.1.26 For CTN I, the final refinement  
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Table 1 Summary of the crystallisation methods used to produce  
physical forms of CTN  
included a total of 97 parameters (29 profile, 3 cell, 1 scale, 1 
overall isotropic temperature factor, 9 preferred orientation, 54  
coordinates), yielding a final Rwp = 4.1. For CTN II, the final  
refinement included a total of 112 parameters (44 profile,  
4 cell, 1 scale, 1 overall isotropic temperature factor, 8 pre-  
ferred orientation, 54 coordinates), yielding a final Rwp = 4.0.  
The resulting structures of form I and II were further  
scrutinised by allowing all fractional coordinates to refine  
freely (Rwp = 3.0 and 2.9 for CTN I and II respectively). As  
expected, the improved Rwp came at the expense of some  
chemical sense, but otherwise, the geometry of the indepen-  
CTN form  
Form I  
 
Form II  
 
 
 
Form III  
 
CTN formic acid solvate  
(1 : 1)  
CTN monohydrate  
 
a 
Method of preparation  
By slurrying CTNa in isoamyl alcohol  
for 7 days  
a) By slurrying CTNa in butyl acetate  
for 14 days  
b) By dehydration of CTN monohydrate  
in an oven at 383 K for 2 hours  
Rapid dehydration of creatine  
monohydrate at 453 Kb  
Solution crystallisation of CTNa in  
formic acidc  
Solution crystallisation of CTNa in water  
dent molecules was well preserved, confirming the correctness  
of the restrained refined crystal structure.27  
 
 
Single crystal X-ray diffraction  
X-ray data were collected at 123 K with graphite monochro-  
matic Mo K
1
 radiation (wavelength Mo K
1
,  = 0.71073 Å) on  
a BRUKER APEX II diffractometer equipped with a CCD detec-  
tor and an Oxford Cryostream variable temperature device. Data 
reduction and cell refinement were performed using BRUKER 
SMART and SAINT programs.28 Multi-scan absorption correction 
were applied with the program SADABS.28 The struc- ture was 
solved by direct methods using SHELXS-97 (ref. 29) and refined 
against F2 using SHELXL-97 (ref. 29) within WinGX.30 All non-
hydrogen atoms were refined anisotropically.  
 
XPac analysis  
XPac11 was used to analyse the crystal packing of all physical  
forms of CTN. Due to the similar conformations of the CTN 
molecules in each structure, all nine non-hydrogen atoms 
(Scheme 1) were selected to provide a common ordered set of 
points (COSPs). The COSPs are the basis of the XPac method and 
describe the geometry of the common CTN component in each 
structure. The standard cut-off parameters were used to identify 
similarities in the angular relationships between CTN molecules in 
the structures.  
Result and discussion  
Preparation of physical forms  
Physical form screening of CTN resulted in three poly-  
morphs, one monohydrate and one formic acid solvate (1/1). 
Methods of preparation for various physical forms are 
summarised in Table 1.  
Fig. 1 shows an overlay of a diagnostic region (12-20° 2)  
of the experimental XRPD patterns of the anhydrous forms of  
CTN, CTN monohydrate and creatinine. All three anhydrous forms 
of CTN were confirmed to be CTN by IR spectroscopy. CTN 
formic acid solvate could only be obtained as a mixture with CTN 
monohydrate although a single crystal of CTN formic acid solvate 
was extracted from the mixture and used to solve the structure. 
XRPD data for the mixed phase sample  
are given in the ESI† (Fig. S3).  
 
 
  
CTN purchased from Sigma was used. b Form III was observed  
from desolvation of a sample of CTN monohydrate loaded in a capillary and 
transferred directly to 453 K. On cooling the same sample within capillary to 
room temperature, form III did not transform back to CTN monohydrate. 
Although in presence of water, it converted back to CTN monohydrate 
immediately. c CTN formic acid solvate was not obtained as a pure phase, 
therefore only its crystal structure is discussed here.  
 
 
The crystal structures of forms I and II were solved using the 
SDPD approach. Fig. 2 and 3 show the final fits to the experimen- 
tal data of the Rietveld-refined structures of CTN I and II. XRPD 
pattern of CTN III could not be indexed and only characteristic  
powder pattern is presented (see ESI,† Fig. S4). Crystallographic  
data for CTN I, II and the CTN formic acid (1/1) solvate are  
summarised in Table 2. Thermal analyses of CTN I, II, III and  
CTN formic acid solvate are shown in Fig. S5 and S6 in the ESI.†  
 
Relative stability  
A polycrystalline sample of CTN II stored in an open vial at  
room temperature converted to CTN monohydrate within  
approximately 3 months (see ESI,† Fig. S7). In contrast, a sam-  
ple of CTN I was unchanged after a year (see ESI,† Fig. S8),  
confirming its higher stability over CTN II.  
 
Competitive slurry experiments  
A 1 : 1 mixture of CTN I and II was suspended in isoamyl  
alcohol or butyl acetate at room temperature showed com- plete 
conversion to CTN I, confirming it is the more stable  
form (see ESI,† Fig. S9 and S10).  
 
Anhydrate  monohydrate phase transformation-moisture  
sorption/desorption experiments  
A more detailed investigation of the transformation between  
CTN I and II and the monohydrate was carried out using DVS. 
Samples of both polymorphs were exposed to relative  
humidities between 0 to 90% RH at 298 K. The sorption-  
desorption isotherms of CTN II show a typical hysteresis cycle  
where at RH > 30% it transforms to CTN monohydrate and  
at low RH (< 20%), the water of the monohydrate is released  
to give form II CTN which was confirmed using XRPD  
(Fig. 4). The measured mass loss corresponds to 14% which is 
equivalent to one mole of water.  
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Fig. 1 Diagnostic region in the XRPD patterns of creatinine, CTN forms I, II and III and CTN monohydrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Final observed (points) and calculated (line) and difference [(y
obs
  y
calc
)/(y
obs
)] profiles for the restrained Rietveld refinement of CTN I.  
 
 
The sorption-desorption isotherm for CTN I shows more  
complex behaviour. The sample shows no significant mass  
change until 60% R.H. Between 60 to 80% R.H. the sample 
increases in mass by 14% as a result of the transformation to  
the monohydrate. During desorption, at R.H. < 20% the water  
molecules in the monohydrate structure are released during  
 
 
 
 
the transformation to anhydrous CTN II. The 2nd DVS cycle fol- 
lows the similar trend as observed with phase changes between 
CTN monohydrate and CTN II. This transformation of CTN II 
(obtained by in situ desolvation) to CTN monohydrate occurs at 
40% R.H., ca. 10% R.H. higher than the original CTN II sample 
(obtained by solution recrystallisation). These differences in  
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Fig. 3 Final observed (points) and calculated (line) and difference [(y
obs
  y
calc
)/(y
obs
)] profiles for the restrained Rietveld refinement of CTN II.  
 
Table 2 Crystallographic data for CTN I, II and formic acid solvate  
 
 
Chemical formula  
Formula mass 
Crystal system  
a/Å b/Å 
c/Å  
/°  
/° /°  
Unit cell volume/Å3  
Temperature/K  
Space group  
No. of formula units per unit cell, Z  
Number of reflections  
Step size  
Radiation wavelength (Å)  
R factors and goodness of fit  
 
 
Background treatment  
 
CTN I  
 
C4H9N3O2  
131.14  
Orthorhombic  
11.9450(2)  
9.5273(1) 
5.3438(1)  
90 90 
90  
608.14(1)  
298  
Pn21a  
4 
142  
0.017°  
Cu K1 
Rwp = 0.041 
Rexp = 0.020  
Rp = 0.034  
Chebyshev polynomial  
 
CTN II  
 
C4H9N3O2  
131.14  
Monoclinic  
9.8450(3) 
5.8373(2)  
11.6698(3)  
90  
105.723(2)  
90  
645.55(3)  
298  
P21/c  
4 
281  
0.017°  
Cu K1 
Rwp = 0.040 
Rexp = 0.011  
Rp = 0.037  
Chebyshev polynomial  
 
CTN formic acid solvate  
 
C4H9N3O2·CH2O2  
177.17  
Orthorhombic  
17.4929(14)  
4.7791(4)  
10.1101(8)  
90 90 
90  
845.21(12)  
123 (2)  
Pna21  
4 
3138  
— 
Mo K  
R[F2 > 2(F2)] = 0.040  
wR(F2) = 0.083  
S = 1.01  
— 
 
 
desolvation kinetics can be attributed to differences in the par- 
ticles used in the two experiments.  
 
 
Crystal structure analysis  
The packing arrangements of the CTN molecules in the three  
novel structures were compared with each other and the previ- 
ously characterised monohydrate structure using XPac program. 
XPac identifies common zero, one, two and three-dimensional (0-, 
1-, 2- and 3-D) geometric arrangements of molecules termed  
 
 
  
 
 
Supramolecular Constructs (SCs).31,32 A 1-D SC, A0, is found in all 
four CTN structures and is considered to be the primary SC  
and all four structures result from different packing arrange-  
ments of this construct (Fig. 5). A0 comprises a zig-zag hydrogen  
bonded chain of CTN molecules composed of NH⋯O hydrogen  
bonds from each NH2 group of the guanidinium cation to the  
carboxylate anion O atoms of the adjacent CTN zwitterion  
 
forming an R
 2 8  motif.33 These hydrogen bonds in each of  
2 
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Fig. 4 DVS isotherm plots for CTN anhydrous forms. Various symbols on sorption and desorption curves correspond to data points that fulfils the preset 
equilibrium condition (mass change < 0.001%). Cycles started using the (a) CTN II and (b) CTN I.  
 
 
the four forms have similar N(-H)⋯O bond lengths with values in 
the range 2.775-2.999 Å. The axis of propagation of this  
hydrogen bonded chain defines the t
1
 translation vector of A0.  
CTN formic acid solvate (top left, Fig. 5) is significantly  
different from CTN I, II and the monohydrate. In this case  
the A0 chains are linked into a 2-D hydrogen-bonded sheet  
along the crystallographic b,c-plane by N-H⋯O hydrogen  
bonds. These hydrogen bonds are formed between hydrogen  
atom of NH2 group and one carboxylate O atom of the CTN  
molecule adjacent in the b-direction with the second  
guanidinium NH2 hydrogen forms H-bond with the carbonyl  
O atom of a formic acid molecule in the b direction. The formic acid 
molecule in turn forms an O-H⋯O hydrogen  
bond to a second creatine molecule. This terminates the  
intermolecular hydrogen bonding along the a-axis resulting in the 
structure being composed of repeating hydrogen bonded and non-
bonded layers.  
CTN I, II and the monohydrate all contain the higher-  
dimensional 2-D SC A1 in which the A0 chains stack along a  
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second axis perpendicular to t
1
, defined as vector t
2
, along the  
b-axis in CTN II and the monohydrate and along the c-axis in  
CTN I (Fig. 5). In CTN I, the A1 layers stack in parallel along  
the a-axis with the methyl groups in each A1 layer oriented in  
the b direction. In CTN II and the monohydrate, the A1 con-  
structs are stacked along the a-axis and neighbouring layers  
are related by 21 symmetry along the axis. This results in a dif-  
ferent arrangement of A1 constructs with the methyl groups 
pointing in the b and b directions in alternate layers.  
In CTN II and CTN monohydrate two A1 layers oriented in  
opposite directions along b, hydrogen bonded to each other  
through NH⋯O contacts perpendicular to the t
1
, t
2
 plane  
(crystallographic a-axis) to form the bilayer A2. In CTN II, the  
A2 bilayers are directly hydrogen bonded to each other through 
NH⋯O contacts while in CTN monohydrate water molecules  
are positioned between the bilayers forming hydrogen bonds  
between amine and carboxylate groups on the neighbouring 
bilayers. This difference in interlayer hydrogen bond connec- tivity 
changes the relative positions of the bilayers along the  
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Fig. 5 Diagram illustrating the structural relationships between CTN I, II, CTN monohydrate and CTN formic acid solvate.  
 
 
a-axis, restricting the crystal packing similarity to 2-D. Data for the 
base vectors of these constructs are given in ESI† (Table S4).  
The crystal structures of CTN II and CTN monohydrate  
show the greatest similarity amongst all the physical forms of 
CTN. The two structures differ only by the presence of a layer  
of water molecules between A2 bilayers in CTN monohydrate.  
This close structural relationship between the crystal structures  
provides an explanation for the preferential desolvation of CTN 
monohydrate to produce CTN II observed from the DVS 
experiments. When water is removed from CTN monohydrate the 
structure collapses to CTN II. This facile transformation 
mechanism also explains why form II transforms to the mono- 
hydrate during storage under ambient conditions. Form I is stable 
under a wider range of % R.H which may be as a result of the 
greater structural rearrangement required to transform  
the A1 to A2 SCs in CTN I and the monohydrate respectively.  
CSP clearly has an increasing role in the investigation of  
physical form diversity in molecular materials and it is 
encouraging that a CSP study of CTN9 successfully predicted the 
CTN II structure allowing the crystal structure to be con- firmed by 
Rietveld refinement against experimental powder data. In contrast, 
in this work CTN II has been determined and verified from 
powder data using direct space methods and periodic density 
functional theory calculations respec- tively. The prediction and 
experimental structure are in good  
agreement with an RMSD15 of 0.117 Å.  
Whilst CTN II was predicted as the thermodynamically  
most stable form, CTN I was not found in the search. This is  
 
 
  
 
 
most likely because the study was restricted to only 5 com- monly 
observed space groups for crystal structures of organic  
zwitterions and excluded Pn21a in which CTN I packs.  
 
Conclusions  
 
A multidisciplinary study of CTN using experimental 
crystallisation coupled with VT-XRPD has led to the discovery of 
three polymorphic forms of CTN and a formic acid solvate. 
Accurate structure determination is vital for better under- standing 
of the basic science underpinning solid-state diver- sity and SDPD 
has provided access to accurate structural information for CTN I 
and II in the absence of suitable single crystals. Further work is 
ongoing to obtain the structure of CTN III and enable comparison 
with the known structures  
and reveal whether it is also based on SC A1 or on an alterna-  
tive packing motif.  
Understanding the relationship between structure and 
properties is a key driver for the investigation of the crystal 
structure of molecular solids. Here the structural relation- ships 
between CTN I, II and CTN monohydrate has provided insight into 
the desolvation mechanism of CTN monohydrate and the increased 
relative stability of CTN I upon exposure to elevated % R.H. 
compared with CTN II. This knowledge has important implications 
for effective physical form purity dur- ing crystallisation, product 
handling and manufacture and on subsequent storage and the 
subsequent product perfor- mance of this widely used oral 
nutritional supplement.  
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